Efficacy and Safety of Low Dose Subcutaneous Diclofenac in the Management of Acute Pain: A Randomized Double-Blind Trial

Pain Practice ◽  
2013 ◽  
Vol 14 (4) ◽  
pp. 315-323 ◽  
Author(s):  
Thomas Dietrich ◽  
Rachel Leeson ◽  
Barbara Gugliotta ◽  
Birte Petersen
Keyword(s):  
Acute Pain ◽  
Low Dose ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial

S601 EFFICACY AND SAFETY OF A SUBCUTANEOUS DICLOFENAC FORMULATION IN THE MANAGEMENT OF ACUTE PAIN: A RANDOMISED, DOUBLE-BLIND TRIAL

2011 ◽  
Vol 5 (S1) ◽  
pp. 269-270
Author(s):  
T. Dietrich ◽  
R. Leeson ◽  
B. Zielińska-Kaźmierska ◽  
M. Opadczuk ◽  
E. Kozieł ◽  
...  
Keyword(s):  
Acute Pain ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

1997 ◽  
Vol 171 (1) ◽  
pp. 73-77 ◽  
Author(s):  
I. Pelc ◽  
P. Verbanck ◽  
O. Le Bon ◽  
M. Gavrilovic ◽  
K. Lion ◽  
...  
Keyword(s):  
Animal Models ◽  
Alcohol Drinking ◽  
Double Blind Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Blind Trial ◽  
Efficacy Parameters ◽  
Clinical Conditions ◽  
Alcohol Dependent

BackgroundAcamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.MethodIn order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).ResultsFor all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.ConclusionThis study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

Sign in / Sign up

Export Citation Format

Share Document